Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from BriaCell Therapeutics ( (TSE:BCT) ) is now available.
BriaCell Therapeutics Corp. has announced a proposed share consolidation to maintain compliance with Nasdaq listing requirements. The consolidation, which involves converting every ten pre-consolidation shares into one post-consolidation share, is expected to take effect on August 25, 2025, pending approval from the Toronto Stock Exchange and Nasdaq. This move is anticipated to impact the trading of the company’s shares on both exchanges, with no fractional shares being issued.
The most recent analyst rating on (TSE:BCT) stock is a Buy with a C$225.00 price target. To see the full list of analyst forecasts on BriaCell Therapeutics stock, see the TSE:BCT Stock Forecast page.
Spark’s Take on TSE:BCT Stock
According to Spark, TipRanks’ AI Analyst, TSE:BCT is a Neutral.
BriaCell Therapeutics has a challenging financial position with no revenue and consistent losses, heavily impacting its stock score. Despite this, recent corporate developments in cancer treatment provide some potential upside. Technical indicators are mixed, and valuation concerns persist with a negative P/E ratio. The company’s reliance on external financing is a notable risk.
To see Spark’s full report on TSE:BCT stock, click here.
More about BriaCell Therapeutics
BriaCell Therapeutics Corp. is a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care.
Average Trading Volume: 26,586
Technical Sentiment Signal: Sell
Current Market Cap: C$18.08M
Find detailed analytics on BCT stock on TipRanks’ Stock Analysis page.